Read-Gene (WAR:RDG) Cyclically Adjusted Revenue per Share: zł0.97 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WAR:RDG Read-Gene SA WAR:RDG
79 GF Score
Price zł5.16
GF Value zł6.45
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Read-Gene Cyclically Adjusted Revenue per Share?

Read-Gene WAR:RDG +1.18% 79 Cyclically Adjusted Revenue per Share is zł0.97 as of Jun. 2026. GuruFocus rates WAR:RDG with a GF Score™ of 79/100 and a GF Value™ of zł6.45 (Modestly Undervalued). The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Read-Gene's adjusted revenue per share for the three months ended in Jun. 2026 was zł0.354. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is zł0.97 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Read-Gene's average Cyclically Adjusted Revenue Growth Rate was 15.50% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 19.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Read-Gene was 19.30% per year. The lowest was 12.40% per year. And the median was 15.85% per year.

As of today (2026-09-08), Read-Gene's current stock price is zł5.16. Read-Gene's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was zł0.97. Read-Gene's Cyclically Adjusted PS Ratio of today is 5.32.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Read-Gene was 11.00. The lowest was 4.12. And the median was 5.75.


Read-Gene  (WAR:RDG) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Read-Gene's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=5.16/0.97
=5.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Read-Gene was 11.00. The lowest was 4.12. And the median was 5.75.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Read-Gene Cyclically Adjusted Revenue per Share Related Terms


Read-Gene Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Read-Gene's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Read-Gene Cyclically Adjusted Revenue per Share Chart

Read-Gene Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.55 0.53 0.65 0.78 0.90

Read-Gene Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.84 0.87 0.90 0.95 0.97

WAR:RDG vs VRTX, REGN, MRNA: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Read-Gene's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Read-Gene Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Read-Gene's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Read-Gene's Cyclically Adjusted PS Ratio falls into.


WAR:RDG
79GF Score
Read-Gene SA WAR:RDG
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Read-Gene Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Read-Gene's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.354/162.2800*162.2800
=0.354

Current CPI (Jun. 2026) = 162.2800.

Read-Gene Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.018 99.064 0.029
201612 0.341 100.366 0.551
201703 0.063 101.018 0.101
201706 0.094 101.180 0.151
201709 0.101 101.343 0.162
201712 0.151 102.564 0.239
201803 0.013 102.564 0.021
201806 0.049 103.378 0.077
201809 0.082 103.378 0.129
201812 0.461 103.785 0.721
201903 0.051 104.274 0.079
201906 0.110 105.983 0.168
201909 0.111 105.983 0.170
201912 0.267 107.123 0.404
202003 0.089 109.076 0.132
202006 0.060 109.402 0.089
202009 0.127 109.320 0.189
202012 0.240 109.565 0.355
202103 0.051 112.658 0.073
202106 0.115 113.960 0.164
202109 0.063 115.588 0.088
202112 0.432 119.088 0.589
202203 0.085 125.031 0.110
202206 0.177 131.705 0.218
202209 0.087 135.531 0.104
202212 0.370 139.113 0.432
202303 0.128 145.950 0.142
202306 0.177 147.009 0.195
202309 0.195 146.113 0.217
202312 0.356 147.741 0.391
202403 0.180 149.044 0.196
202406 0.252 150.997 0.271
202409 0.282 153.439 0.298
202412 0.400 154.660 0.420
202503 0.302 157.021 0.312
202506 0.291 157.509 0.300
202509 0.288 158.000 0.296
202512 0.440 158.320 0.451
202603 0.330 163.070 0.328
202606 0.354 162.280 0.354

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of zł0.97 mean?
Read-Gene (WAR:RDG) has a Cyclically Adjusted Revenue per Share of zł0.97 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Read-Gene and its competitors.
Is Read-Gene's Cyclically Adjusted Revenue per Share too high?
Read-Gene's current Cyclically Adjusted Revenue per Share is zł0.97. Overall, Read-Gene has a GF Score™ of 79/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Read-Gene's Cyclically Adjusted Revenue per Share compare to VRTX and REGN?
Read-Gene's Cyclically Adjusted Revenue per Share of zł0.97 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Read-Gene and its competitors. Read-Gene's current Cyclically Adjusted Revenue per Share is zł0.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Read-Gene stock overvalued right now?
Based on GuruFocus' analysis, Read-Gene (WAR:RDG) is currently considered Modestly Undervalued. The stock's GF Value™ is zł6.45, compared to a current price of zł5.16 — trading 20% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is zł0.97. Read-Gene's overall GF Score™ is 79/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Read-Gene (WAR:RDG), the current Cyclically Adjusted Revenue per Share is zł0.97 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Read-Gene (WAR:RDG) Overvalued in 2026?

Based on GuruFocus' analysis, Read-Gene stock appears to be undervalued. The current stock price of zł5.16 is trading 20% below its estimated GF Value™ of zł6.45. GuruFocus considers Read-Gene to be Modestly Undervalued.

Key valuation signals for WAR:RDG:

  • Cyclically Adjusted Revenue per Share: zł0.97
  • GF Value™: zł6.45 vs. price of zł5.16 (20% below fair value)
  • GF Score™: 79/100 with 1 warning sign

No single metric tells the full story. See the WAR:RDG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Read-Gene Business Description

Address Ulica Alabastrowa 8, Grzepnica, Dobra, POL, 72-003
Read-Gene SA treats each patient individually based on genetic tests. The company's segments include chemoprevention, clinical trials and genetic tests. It also engaged in developing technologies to commercialize methods to detect, prevent and treat malignant tumours.
79GF Score

Get the complete analysis for WAR:RDG

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł5.16
Price
zł6.45
GF Value